All In Biotech

Drug Trial Radar · NCT01618370

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Last checked: Nov 20, 2026Latest source record: Mar 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

705

Actual

Start

Jul 22, 2012

Primary completion

Aug 13, 2014

Study completion Feb 28, 2016

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.

Conditions

  • Prostatic Neoplasms

Interventions

  • Radium-223 dichloride (BAY88-8223)Drug

    One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute safety, variables will be summarized using descriptive statistics based on adverse events collectionTime frame: From baseline to 30 days post-treatment
  2. Long-term safety, variables will be summarized using descriptive statistics based on adverse events collectionTime frame: From 30 days post-treatment up to 3 years

Locations

215 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Bruges, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Ottignies, Belgium

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Plzen - Bory, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Herlev, Denmark

  • Site not named

    Odense, Denmark

  • Site not named

    Helsinki, Finland

  • Site not named

    HUS, Finland

  • Site not named

    Kuopio, Finland

  • Site not named

    Seinäjoki, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Angers, France

  • Site not named

    Avignon, France

  • Site not named

    Caen, France

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Grenoble, France

  • Site not named

    La Roche-sur-Yon, France

  • Site not named

    Lille, France

  • Site not named

    Lille, France

  • Site not named

    Montpellier, France

  • Site not named

    Montpellier, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.